Loading organizations...
§ Private Profile · Mountain View, CA, USA
biotechnology company developing redox therapeutics for inherited mitochondrial diseases, focused on mitochondrial dysfunction.
Founded in 2005 by chief executive Guy Miller, Edison Pharmaceuticals is a Mountain View biotechnology company focused on discovering redox therapeutics targeting severe mitochondrial dysfunction. The firm specializes in translational pharmacology to treat pediatric orphan diseases of the mitochondrial respiratory chain, while expanding research into adult neurological conditions sharing common mitochondrial mechanisms. Their lead product candidate EPI-743 advanced through clinical development for pediatric patients, earning the enterprise an award from MitoAction for exemplary service to the mitochondrial disease community. The organization secured capital through equity financing and NIH grants, including a multimillion-dollar Series B round backed by prominent investors Carl Berg and John Marriott III. To accelerate global commercialization, Edison established a strategic partnership with Dainippon Sumitomo Pharma valued at nearly four point three billion dollars to advance a pipeline of over ten new drugs.
Edison Pharmaceuticals has raised $20.0M across 1 funding round.
Edison Pharmaceuticals has raised $20.0M in total across 1 funding round.
Edison Pharmaceuticals has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series F in November 2012.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 26, 2012 | $20M Series F | Mitsui & CO. Global Investment | — | Announced |
Edison Pharmaceuticals has raised $20.0M in total across 1 funding round.
Edison Pharmaceuticals's investors include Mitsui & Co. Global Investment.